This is the authors' abstract. We don't add key points for this paper.
he incidence of melanoma, the most serious form of skin cancer, is rising globally. lthough most patients are diagnosed and treated at an early stage of the disease and have a good prognosis, survival among patients with unresectable or metastatic (advanced) melanoma remains poor. In the United States, an estimated 9,940 deaths from melanoma will occur in 2015; 1 in Europe, melanoma accounts for an estimated 20,000 deaths annually. tients with advanced melanoma historically had a dismal prognosis, with median survival of less than a year. In a meta-analysis of 2,100 patients with advanced melanoma from 42 phase 2 cooperative group clinical trials with accrual closing between 1975 and 2005, the median overall survival (OS) was 6.2 months (95% confdence interval [CI], 5.9-6.5), with 25.5% (95% CI, 23.6-27.4) alive at 1 year. nother recent systematic review estimated median OS for stage IV melanoma of about 8 months,
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Margolin et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: